

# **CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others) Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33,HER1, HER2, MESO, EGFRvII) Companies (Novartis,Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)**

<https://marketpublishers.com/r/C94F06DB7CBEN.html>

Date: August 2018

Pages: 0

Price: US\$ 2,390.00 (Single User License)

ID: C94F06DB7CBEN

## **Abstracts**

CAR T Cell therapy market is expected to grow with a CAGR of over 46 percent in the forecast period. Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking this big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.

Rising number of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR T Cell therapy market; however high cost of CAR T cell therapy treatment and regulatory challenges are key inhibitors for this market.

Renub Research latest study report "CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII,

Others) Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33,HER1, HER2, MESO, EGFRvII) Companies (Novartis,Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)” provides a detailed and comprehensive insight of the global CAR T cell therapy market.

This report studies the Global CAR T cell therapy market from 2 key view points by CAR T cell therapy market and CAR T cell therapy studies. Market segments are further studied by geographical regions and targeted antigens whereas CAR T cell therapy studies by targeted antigens globally and China specific. The report provides a complete analysis of the key Growth Drivers and Challenges, SWOT analysis, market, and their projections for the upcoming years (2028).

The report has been analyzed from 9 major viewpoints

1. Targeted Antigen - Global CAR T Cell Therapy Market
2. Regional CAR T Cell Therapy Market
3. Global – CAR T Cell Therapy Clinical Trials/Study
4. China CAR T Cells Clinical Trials Details
5. CAR T Cell Therapy SWOT Analysis
6. The Regulation in CAR T Cell Therapy
7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
8. Growth Drivers and Challenges
9. Key CAR T companies Initiatives and Financial Insight

Targeted Antigens - Global CAR T Cell Therapy Market & Forecast

CD19

CD20

GD2

CD22

CD30

CD33

HER2

MESO

EGFRvII

Others

## Regional CAR-T Cell Therapy Market & Forecast

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

## Global – CAR T Cell Therapy Clinical Trials/Study

CD19

CD20

GD2

CD22

CD30

CD33

HER1

HER2

MESO

EGFRvII

## China CAR T Cells Clinical Trials Details

By Cities CAR T Cells Clinical Trials

CD19 Directed CAR T Cells Clinical Trials

Non-CD19 Directed CAR T Cells Clinical Trials

Solid Tumors CAR T Cells Clinical Trials

## The Regulation in CAR T Cell Therapy

United States

European Union

China

## IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

Venture Capital Investment

Initial Public Offerings

Strategic Partnerships/Deals

Key CAR T Technology Deals

Key Companies covered in this report are

Novartis

Gilead Sciences (Kite Pharma)

Celgene Corporation (Juno Therapeutics)

Celyad

## Contents

### 1. EXECUTIVE SUMMARY

### 2. GLOBAL CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MARKET

### 3. MARKET SHARE – CAR-T CELL THERAPY

#### 3.1 By Geographical Region

#### 3.2 By Targeted Antigens

### 4. TARGETED ANTIGEN MARKET

#### 4.1 CD19

##### 4.1.1 Introduction

##### 4.1.2 Market Size and Forecast

#### 4.2 CD20

##### 4.2.1 Introduction

##### 4.2.2 Market Size and Forecast

#### 4.3 GD2

##### 4.3.1 Introduction

##### 4.3.2 Market Size and Forecast

#### 4.4 CD22

##### 4.4.1 Introduction

##### 4.4.2 Market Size and Forecast

#### 4.5 CD30

##### 4.5.1 Introduction

##### 4.5.2 Market Size and Forecast

#### 4.6 CD33

##### 4.6.1 Introduction

##### 4.6.2 Market Size and Forecast

#### 4.7 HER2

##### 4.7.1 Introduction

##### 4.7.2 Market Size and Forecast

#### 4.8 Mesothelin (MESO)

##### 4.8.1 Introduction

##### 4.8.2 Market Size and Forecast

#### 4.9 EGFRvIII

##### 4.9.1 Introduction

- 4.9.2 Market Size and Forecast
- 4.10 Others
  - 4.10.1 Market Size and Forecast

## **5. GEOGRAPHICAL CAR-T CELL THERAPY MARKET (2016 -2026)**

- 5.1 North America
- 5.2 Europe
- 5.3 Asia Pacific
- 5.4 Latin America
- 5.5 Middle East
- 5.6 Africa

## **6. GLOBAL - CAR-T CELL CLINICAL TRIALS/STUDY**

- 6.1 CD19
- 6.2 CD20
- 6.3 CD22
- 6.4 CD30
- 6.5 CD33
- 6.6 EGFRvIII
- 6.7 GD2
- 6.8 HER1
- 6.9 HER2
- 6.10 MESO

## **7. CHINA CAR-T CELLS CLINICAL TRIALS DETAILS**

- 7.1 By Cities CAR-T Cells Clinical Trials
- 7.2 CD19 Directed CAR-T Cells Clinical Trials
- 7.3 Non-CD19 Directed CAR-T Cells Clinical Trials
- 7.4 Solid Tumors CAR-T Cells Clinical Trials

## **8. CAR-T CELL THERAPY SWOT ANALYSIS**

- 8.1 Strength
- 8.2 Weakness
- 8.3 Opportunities
- 8.4 Threats

## **9. REGULATION IN CAR-T CELL THERAPY**

- 9.1 United States
- 9.2 European Union
- 9.3 China

## **10. IPO/INVESTMENT/FUNDING/PARTNERSHIP IN CAR-T CELL THERAPY MARKET**

- 10.1 Venture Capital Investment
- 10.2 Initial Public Offerings of CAR-T Companies
- 10.3 CAR-T Companies Strategic Partnerships/Deals
- 10.4 Key CAR-T Technology Deals

## **11. GROWTH DRIVERS**

- 11.1 FDA Approvals of CAR-T Therapy
- 11.2 Dramatically Increasing Number of CAR-T Cell Trials Globally

## **12. CHALLENGES**

- 12.1 Regulatory Challenges
- 12.2 Very Expensive CAR-T Therapy Treatment

## **13. NOVARTIS**

- 13.1 Company Overview
- 13.2 Initiatives
  - 13.2.1 Point
  - 13.2.2 Point
- 13.3 Financial Insight

## **14. GILEAD SCIENCES (KITE PHARMA)**

- 14.1 Company Overview
- 14.2 Company Initiatives
  - 14.2.1 Point
  - 14.2.2 Point



14.2.3 Point

14.3 Company Financial Insight

## **15. CELGENE CORPORATION (JUNO THERAPEUTICS)**

15.1 Company Overview

15.2 Company Initiatives

15.2.1 Point

15.2.2 Point

15.3 Company Financial Insight

## **16. CELYAD**

16.1 Company Overview

16.2 Company Initiatives

16.2.1 Point

16.2.2 Point

16.3 Financial Insight

## List Of Figures

### LIST OF FIGURES:

Figure 2-1: Global – CAR-T Cell Therapy Market & Forecast (Million US\$), 2017 – 2028

Figure 3-1: Global – Current & Forecast for CAR-T Cell Therapy Regional Market Share (Percent), 2017 – 2028

Figure 4-1: Global – Current & Forecast for CD19 Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-2: Global – Current & Forecast for CD20 Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-3: Global – Current & Forecast for GD2 Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-4: Global – Current & Forecast for CD22 Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-5: Global – Current & Forecast for CD30 Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-6: Global – Current & Forecast for CD33 Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-7: Global – Current & Forecast for HER2 Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-8: Global – Current & Forecast for MESO Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-9: Global – Current & Forecast for EGFRvIII Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 4-10: Global – Current & Forecast for Others Antigen CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 5-1: North America – Current & Forecast for CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 5-2: Europe – Current & Forecast for CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 5-3: Asia Pacific – Current & Forecast for CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 5-4: Latin America – Current & Forecast for CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 5-5: Middle East – Current & Forecast for CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

Figure 5-6: Africa – Current & Forecast for CAR-T Cell Therapy Market (Million US\$), 2017 – 2028

- Figure 7-1: China – By Cities CAR-T Cells Clinical Trials (Number), 2017
- Figure 11-1: Global – CAR-T New & Total Clinical Trials (Number), 2012-2017
- Figure 11-2: Global – By Phase CAR-T Clinical Trials (Number), 2017
- Figure 13-1: Novartis – Global Sales (Million US\$), 2013 - 2017
- Figure 13-2: Novartis – Forecast for Global Sales (Million US\$), 2018 - 2028
- Figure 14-1: Gilead Sciences – Global Sales (Million US\$), 2013 - 2017
- Figure 14-2: Gilead Sciences – Forecast for Global Sales (Million US\$), 2018 - 2028
- Figure 15-1: Celgene – Global Sales (Million US\$), 2013 - 2017
- Figure 15-2: Celgene – Forecast for Global Sales (Million US\$), 2018 - 2028
- Figure 16-1: Celyad – Global Sales (Million US\$), 2013 - 2017
- Figure 16-2: Celyad – Forecast for Global Sales (Million US\$), 2018 - 2028

## List Of Tables

### LIST OF TABLES:

Table 3-1: Global – Current & Forecast for CAR-T Cell Therapy Targeted Antigens Market Share (Percent), 2017 – 2028

Table 6-1: Global – Details of CD19 CAR-T Studies, 2018

Table 6-2: Global – Details of CD20 CAR-T Studies, 2018

Table 6-3: Global – Details of CD22 CAR-T Studies, 2018

Table 6-4: Global – Details of CD30 CAR-T Studies, 2018

Table 6-5: Global – Details of CD33 CAR-T Studies, 2018

Table 6-6: Global – Details of EGFRvIII CAR-T Studies, 2018

Table 6-7: Global – Details of GD2 CAR-T Studies, 2018

Table 6-8: Global – Details of HER1 CAR-T Studies, 2018

Table 6-9: Global – Details of HER2 CAR-T Studies, 2018

Table 6-10: Global – Details of MESO CAR-T Studies, 2018

Table 7-1: China - CD19 Directed CAR-T Cells Clinical Trials, 2017

Table 7-2: China – Non-CD19 Directed CAR-T Cells Clinical Trials, 2017

Table 7-3: China – Solid Tumors CAR-T Cells Clinical Trials, 2017

Table 10-1: Global – Venture Capital Investments (Million US\$) in CAR-T Cell Therapy, 2011 – 2017

Table 10-2: Global – Initial Public Offerings (Million US\$) in CAR-T Cell Therapy, 2011 – 2016

Table 10-3: Global - CAR-T Companies Strategic Partnerships/Acquisitions, 2012-2017

Table 10-4: Global – Key CAR-T Technology Deals, 2012-2017

## I would like to order

Product name: CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others) Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33,HER1, HER2, MESO, EGFRvII) Companies (Novartis,Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)

Product link: <https://marketpublishers.com/r/C94F06DB7CBEN.html>

Price: US\$ 2,390.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C94F06DB7CBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970